Project UpdateJun 29, 2026, 08:36 AM
Alaunos ALN1003 Preclinical Data Shows Lower Liver Weight
AI Summary
Alaunos Therapeutics announced new preclinical statistical analysis for its investigational oral metabolic candidate, ALN1003. The analysis showed ALN1003-treated animals had lower liver weight after adjustment for body fat percentage, consistent with previously disclosed positive findings related to liver injury, NAFLD Activity Scores, insulin resistance, and adipose endocrine signaling. While these non-GLP findings support further evaluation, the company also disclosed a cash position of $0.354 million as of March 31, 2026, and plans to seek additional financing.
Key Highlights
- ALN1003-treated animals showed lower liver weight (p=0.000005) after body fat adjustment in mice.
- Findings are consistent with previously reported lower liver injury enzymes (ALT, AST, ALP).
- Consistent with lower NAFLD Activity Scores (NAS) (2.7 vs 5.0 for controls).
- Consistent with lower HOMA-IR (p=0.0006) after body fat adjustment for insulin resistance.
- Consistent with favorable adipose endocrine signaling (lower leptin, higher adiponectin).
- Company had cash and cash equivalents of approximately $0.354 million as of March 31, 2026.
- Alaunos Therapeutics intends to pursue additional financing to support program advancement.
Price Impact
More from TCRT